Gene · 55869
Papers3,134
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
661 to 680 of 3,134
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Gene regulation by histone-modifying enzymes under hypoxic conditions: a focus on histone methylation and acetylation. | Exp Mol Med | 2022 | 35869366 | PubTator, text mining | PubMed |
| Target-based in-silico screening of basil polysaccharides against different epigenetic targets responsible for breast cancer. | J Recept Signal Transduct Res | 2022 | 35862239 | PubTator, text mining | PubMed |
| Mitochondrial Function and Microbial Metabolites as Central Regulators of Intestinal Immune Responses and Cancer. | Front Microbiol | 2022 | 35847099 | PubTator, text mining | PubMed |
| Development of a Novel Sphingolipid Signaling Pathway-Related Risk Assessment Model to Predict Prognosis in Kidney Renal Clear Cell Carcinoma. | Front Cell Dev Biol | 2022 | 35846357 | PubTator, text mining | PubMed |
| Comprehensive Computational Analysis of Honokiol Targets for Cell Cycle Inhibition and Immunotherapy in Metastatic Breast Cancer Stem Cells. | Evid Based Complement Alternat Med | 2022 | 35845599 | PubTator, text mining | PubMed |
| EPAC Regulates Melanoma Growth by Stimulating mTORC1 Signaling and Loss of EPAC Signaling Dependence Correlates with Melanoma Progression. | Mol Cancer Res | 2022 | 35834616 | PubTator, text mining | PubMed |
| Epigenetic Effects of Addictive Drugs in the Nucleus Accumbens. | Front Mol Neurosci | 2022 | 35813068 | PubTator, text mining | PubMed |
| HDAC Inhibitory and Anti-Cancer Activities of Curcumin and Curcumin Derivative CU17 against Human Lung Cancer A549 Cells. | Molecules | 2022 | 35807258 | PubTator, text mining | PubMed |
| cAMP Signaling in Cancer: A PKA-CREB and EPAC-Centric Approach. | Cells | 2022 | 35805104 | PubTator, text mining | PubMed |
| Histone deacetylase 3 promotes alveolar epithelial-mesenchymal transition and fibroblast migration under hypoxic conditions. | Exp Mol Med | 2022 | 35804191 | PubTator, text mining | PubMed |
| Distinct biochemical properties of the class I histone deacetylase complexes. | Curr Opin Chem Biol | 2022 | 35803024 | PubTator, text mining | PubMed |
| Reshaping the systemic tumor immune environment (STIE) and tumor immune microenvironment (TIME) to enhance immunotherapy efficacy in solid tumors. | J Hematol Oncol | 2022 | 35799264 | PubTator, text mining | PubMed |
| Recent progress on vascular endothelial growth factor receptor inhibitors with dual targeting capabilities for tumor therapy. | J Hematol Oncol | 2022 | 35799213 | PubTator, text mining | PubMed |
| Design, synthesis and biological evaluation of quinoline-2-carbonitrile-based hydroxamic acids as dual tubulin polymerization and histone deacetylases inhibitors. | Eur J Med Chem | 2022 | 35797900 | PubTator, text mining | PubMed |
| Nuclear Coregulatory Complexes in Tregs as Targets to Promote Anticancer Immune Responses. | Front Immunol | 2022 | 35795673 | PubTator, text mining | PubMed |
| CKD-581 Downregulates Wnt/β-Catenin Pathway by DACT3 Induction in Hematologic Malignancy. | Biomol Ther (Seoul) | 2022 | 35794797 | PubTator, text mining | PubMed |
| Glioblastoma: Current Status, Emerging Targets, and Recent Advances. | J Med Chem | 2022 | 35786935 | PubTator, text mining | PubMed |
| PHF5A Contributes to the Maintenance of the Cancer Stem-like Phenotype in Non-Small Cell Lung Cancer by Regulating Histone Deacetylase 8. | Ann Clin Lab Sci | 2022 | 35777798 | PubTator, text mining | PubMed |
| Discovery of pomalidomide-based PROTACs for selective degradation of histone deacetylase 8. | Eur J Med Chem | 2022 | 35759908 | PubTator, text mining | PubMed |
| Insights Into Platelet-Derived MicroRNAs in Cardiovascular and Oncologic Diseases: Potential Predictor and Therapeutic Target. | Front Cardiovasc Med | 2022 | 35757325 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/55869/papers?page=34